U.S., May 24 -- ClinicalTrials.gov registry received information related to the study (NCT06986434) titled 'CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms' on May 15.
Brief Summary: This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.
Study Start Date: May 22
Study Type: INTERVENTIONAL
Condition:
Relapsed or Refractory Plasma Cell Neoplasms
Intervention:
GENETIC: CAR19BCMA-T cells
CAR19BCMA-T cells Each subject will be infused with single dose of CD19BCMA-CAR-T cells. A classic "3+3" dose escalation will be employed. The low dose is 1x10^6 /kg, the medium dose is 2x10^6 /kg, and the high dose is ...